Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response-Reference-Cited by-同舟云学术

Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response

Published:2015-12-31 Issue:2 Volume:77 Page:365-374
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Perroud Herman Andres,Alasino Carlos Maria,Rico Maria Jose,Mainetti Leandro Ernesto,Queralt Francisco,Pezzotto Stella Maris,Rozados Viviana Rosa,Graciela Scharovsky O.

Funder

Agencia Nacional de Promoción Científica y Tecnológica (ANPCyT)

The National Cancer Institute at the National Institutes of Health.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-015-2947-9.pdf

Reference40 articles.

1. Palumbo R, Sottotetti F, Riccardi A, Teragni C, Pozzi E, Quaquarini E, Tagliaferri B, Bernardo A (2013) Which patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians. Ther Adv Med Oncol 5(6):334–350. doi: 10.1177/1758834013508197

2. Nelson R (2013) Targeted therapies offer promise, but are they affordable? Medscape. http://www.medscape.com/viewarticle/810147#vp_2 . Accessed March 13 2015

3. Hanahan D, Bergers G, Bergsland E (2000) Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. J Clin Invest 105(8):1045–1047. doi: 10.1172/JCI9872

4. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nole F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de Braud F, Viale G, Goldhirsch A (2002) Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 13(1):73–80

5. Perroud HA, Rico MJ, Alasino CM, Queralt F, Mainetti LE, Pezzotto SM, Rozados VR, Scharovsky OG (2013) Safety and therapeutic effect of metronomic chemotherapy with cyclophosphamide and celecoxib in advanced breast cancer patients. Future Oncol 9(3):451–462. doi: 10.2217/fon.12.196

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association of COX-inhibitors with cancer patients’ survival under chemotherapy and radiotherapy regimens: a real-world data retrospective cohort analysis;Frontiers in Oncology;2024-09-13

2. The Killer’s Web: Interconnection between Inflammation, Epigenetics and Nutrition in Cancer;International Journal of Molecular Sciences;2024-02-27

3. COX 2-inhibitors; a thorough and updated survey into combinational therapies in cancers;Medical Oncology;2024-01-02

4. Metronomic chemotherapy, dampening of immunosuppressive cells, antigen presenting cell activation, and T cells. A quartet against refractoriness and resistance to checkpoint inhibitors;Cancer Letters;2023-11

5. Challenges and Opportunities for Celecoxib Repurposing;Pharmaceutical Research;2023-08-08